Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedNo significant changes detected.SummaryDifference0.5%
- Check15 days agoChange DetectedCore content updated with a government-operating-status notice and a version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%
- Check22 days agoChange Detected- Removed a specific resource topic (Head and neck squamous cell carcinoma) from Genetic and Rare Diseases Information Center resources. - Updated the revision version to v3.1.0.SummaryDifference0.9%
- Check36 days agoChange DetectedThe page now shows Revision: v3.0.2 (replacing v3.0.1), indicating an update. The Back to Top link has been removed, a minor UI change.SummaryDifference0.6%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check51 days agoChange DetectedThe web page has been updated to include new information on various types of cancers, including lung cancer and head and neck squamous cell carcinoma, while removing references to certain cancer types and treatments. Additionally, the facility name and location details have been added.SummaryDifference6%
Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.